TTT-28

• Description:

  TTT-28 is a synthesized thiazole-valine peptidomimetic, a novel selective inhibitor of ABCB1 (P-gp/MDR1) with high efficacy and low toxicity, which reverses the ATP-binding cassette sub-family B member 1 (ABCB1) -mediated multidrug resistance (MDR) by selectively blocking the efflux function of ABCB1[1].

• UNSPSC:

  12352005

• Target:

  P-glycoprotein

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ttt-28.html

• Concentration:

  10mM

• Purity:

  99.87

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  O=C(N[C@@H](C(C)C)C1=NC(C(NC2=CC=CC=C2C(C3=CC=CC=C3)=O)=O)=CS1)C4=CC(OC)=C(OC)C(OC)=C4

• Molecular Formula:

  C31H31N3O6S

• Molecular Weight:

  573.66

• References & Citations:

  [1]Wang YJ, et al. Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1. Sci Rep. 2017 Feb 9;7:42106.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1609138-51-3